September 29, 2016
10:00am PT, 1:00pm ET
One of the challenges with personalized medicine lies in the identification of robust, clinically relevant biomarkers. Traditional approaches to biomarker discovery either focus on only a subset of the potential targets, or have insufficient resolution to discriminate small or rare changes that may carry biological significance.
Recent technological advancement has made high-resolution whole-genome and whole-transcriptome profiling a reality. Translational researchers can now simultaneously search broadly and deeply to efficiently identify potential biomarkers from samples in a matter of days, without requiring resource-intensive bioinformatics support.
During the webinar, Dr. Stewart Neill will:
- Discuss the importance of copy number variation and copy-neutral loss of heterozygosity in the modern classification and subclassification of CNS neoplasia
- Demonstrate how advancements in technologies with greater sensitivity can detect important cytogenomic events that are driving the discovery of novel biomarkers
- Illustrate the use of microarray-based technologies in a clinical research setting through a case study approach
- Answer your questions live during the broadcast!